00 AMD Wait and SeeAdvanced Micro Devices Inc

Every daythe Zacks Equity Research analysts discuss the latest news and events impactingstocks and the financial markets. Stocks recently featured in the blog include:Allianz Aktiengesell (NYSE: AZ), Advanced Micro Devices, Inc. (NYSE: AMD),Schlumberger Limited (NYSE: SLB), Forest Labs (NYSE: FRX)and Cypress Biosciences(NASDAQ: CYPB). Get the most recent insight from Zacks Equity Research with the free Profit fromthe Pros newsletter: are highlights from Thursdays Analyst Blog:Allianz Buy Rec ReiteratedAllianz Aktiengesell (NYSE: AZ) has over 60 million customers and a presence inmore than 70 countries. It is the largest insurer in Germany with a market shareof 18 of the property and casualty insurance in that country, and is a leaderin Europe. We are maintaining our Buy recommendation on Allianz after its third quarterresults.

The recent sharp drop in share price has taken the stock to a veryattractive level, and our Zacks quantitative model also has a Buy on the stock.Our target price is $11.00 AMD Wait and SeeAdvanced Micro Devices, Inc. September quarter results beat theconsensus on both the top and bottom lines Forward guidance is for flattishproduct revenue. The company has disposed off the non-core handset and DTV lines. Managementfocus is now on profitability, which is expected to come from the ramp up of newproducts, favorable mix changes, the transition to 45nm production and the assetsmart strategy.

Schlumberger a Long-Term PlayHouston-based Schlumberger Limited (NYSE: SLB) is a leading oilfield servicescompany, providing technology, project management, and information services tothe global oil and gas industry. We are maintaining our Buy recommendation on Schlumberger shares ahead of thecompany's quarterly results However, we have lowered our fourth-quarter 2008($1.10 vs $1.34) and 2009 ($3.90 vs. $5.50) EPS estimates to reflect asoftening oilfield service environment. Cypress Bio Buy Paying OffAfter the market closed on Wednesday, Forest Labs (NYSE: FRX) and CypressBiosciences (NASDAQ: CYPB) announced FDA approval of Savella (milnacipran) forthe management of fibromyalgia. Once launched, Savella will enter themulti-billion dollar fibromyalgia market, a painful and debilitating conditionaffecting over 6 million Americans annually. Last month we initiated coverage of Cypress Bio at $6.04 with a 'Buy' rating andnear-term $12 price target. Paramount to our thesis was the expected approval ofSavella in early 2009.